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note that 38.7% of patients in this group received 
an additional agent during their hospital stay 
that provided atypical coverage for an average of 
4.5 days. The addition of a macrolide, a fluoro-
quinolone, or doxycycline was accepted as strategy-
compliant if the agent was added for medical 
reasons. Since the study assessed empirical anti-
biotics only, atypical coverage could be added 
after the first day of the hospital stay without 
deviating from the protocol, even in the sub-
group referred to as “antibiotic-adherent.” The 
benefit of beta-lactam monotherapy versus other 
guideline-recommended regimens has historical-
ly centered on the question of whether atypical 
coverage is beneficial.1 It would therefore be use-
ful to know the difference in mortality between 
those in the beta-lactam monotherapy group 
who did not receive additional antibiotics against 
atypical pathogens and those who received beta-
lactam–macrolide or fluoroquinolone.
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To the Editor: In this study, the noninferiority 
margin was 3 percentage points and the expect-
ed mortality was 5%. No clinical rationale for the 
large noninferiority margin was given. The study 
ran from February 2011 to September 2013. An 
article detailing the rationale for the study, but 
not the noninferiority margin, was published in 
April 2014, after the study was completed.1 The 
original protocol, dated May 20, 2010, had speci-
fied a noninferiority margin of 2 percentage points 
at 28 days, and a final protocol, dated September 
21, 2011, which was 7 months after the study had 
started, amended the margin to 3 percentage 
points at 90 days. The large noninferiority margin 
reported in the study is not clinically justified, 
the statistical rationale was published only after 
the trial had been completed, and the noninferi-
ority margin and primary end point were changed 
once the study was under way. This study should 
be therefore interpreted with caution.
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To the Editor: Postma et al. report that beta-
lactam monotherapy is noninferior to beta-lactam–
macrolide combination therapy in patients for 
whom there is a clinical suspicion of CAP and 
even in patients for whom CAP has been radio-
logically confirmed. In a recent clinical trial, 
Garin et al.1 suggested that patients with severe 
pneumonia (Pneumonia Severity Index [PSI] risk 
class IV or score on CURB-65 [confusion, urea, 
respiratory rate, blood pressure, age ≥65 years] of 
≥2) seemed to benefit from combination therapy. 
In a previous systematic review and meta-
analysis, we found that beta-lactam–macrolide 
combination therapy was associated with a de-
creased risk of death among patients with more 
severe (high-severity) CAP.2 However, Postma et al. 
do not indicate the effects of beta-lactam–macro-
lide combination therapy and beta-lactam mono-
therapy in patients with high-severity CAP. Can the 
authors report the numbers of deaths in these two 
groups in different PSI and CURB-65 categories?
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The Authors Reply: Van der Eerden and Piszczek 
and Partlow mention that 38.7% of patients as-
signed to the beta-lactam strategy also received 
non–beta-lactam antibiotics at some time during 
the beta-lactam–strategy period. The protocol al-
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